Completed PHASE1 INTERVENTIONAL 2-arm NCT00846274

Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III

Single-Dose, Open Label, Randomized Comparative Clinical Trial to Evaluate the Tolerability, Safety and PK/PD of Human ATIII Products, SKATIII Injection andATIII Injection in Healthy Male Subjects

Sponsor: Korea University Anam Hospital

Conditions Healthy

Interventions SK Antithrombin III

Updated 7 times since 2017 Last updated: Feb 17, 2009 Started: Oct 31, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Korea University Anam Hospital and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea University Anam Hospital
SK Chemicals Co., Ltd.

Data source: SK Chemicals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea